Osivax publishes positive results from trial of influenza vaccine candidate

Ella Day | July 15, 2025 | News story | Research and Development |  Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases 

French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead candidate. The results have been published in the journal, Vaccines.

In the study, 180 healthy adults aged 18 to 55 years were given either Fluarix Tetra  (hemagglutinin antigen-based inactivated influenza vaccine) with a placebo, Fluarix Tetra and OVX836, or OVX836 and placebo.

Based in Australia, the study demonstrated that the candidate induced complementary immune responses, as well as a favourable safety profile, both when administered alone or in combination with Fluarix Tetra.

Advertisement

“The favourable safety profile and strong immune response observed in this study provide encouraging evidence that OVX836 can be co-administered with a standard seasonal influenza vaccine,” commented Nicola Groth, chief medical officer of Osivax.

“The data collected will support the continued development of OVX836 as we focus on a single-injection formulation that streamlines vaccination delivery and maximises public health impact,” added Alexandre Le Vert, CEO and co-founder of Osivax.

Osivax develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses using its oligoDOM nanoparticle platform technology. Its ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of COVID-19, both respiratory diseases, in one single vaccine.

Ella Day

15/7/25

Related Content

Tridem begins phase Ib trial of Parkinson’s disease vaccine

Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

The Gateway to Local Adoption Series

Latest content